Clinical Trial

Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure

Study acronym: K-PROSE
Recruiting
View on ClinicalTrials.gov →
Summary
The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL/min/1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-07-17
notable Sponsor changed: Seoul National University Bundang Hospital -> Jin Joo Park 2026-07-17
notable Primary completion moved earlier: 2029-01-30 -> 2027-06-30 2026-07-17
minor Completion moved earlier: 2029-01-30 -> 2027-06-30 2026-07-17
Trial Details
NCT Number NCT07550790
Lead Sponsor Jin Joo Park
Conditions Heart Failure Acute, Renal Dysfunction
Enrollment 190 participants
Start Date 2026-07-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-16